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ABSTRACT
The purpose of this study is to investigate the outcomes of penetrating keratoplasty (PKP) fol-
lowing autologous cultivated limbal epithelial stem cell transplantation (CLET). A prospective,
single center, interventional cohort study investigating patients with unilateral total limbal stem
cell deficiency (LSCD) treated with CLET who underwent PKP. Patients with confirmed corneal
re-epithelialization> 6 months post-CLET, and with best-corrected visual acuity (BCVA) <0.3 log-
MAR were offered PKP. CLET survival assessed by slit lamp, corneal impression cytology (CIC),
and in vivo confocal microscopy. Confirmation of corneal re-epithelialization by histological and
immunocytochemical (ICC) examination of trephined corneal buttons. Mean change in best-
corrected visual acuity (logMAR) following PKP and PKP survival at 12 months were calculated.
Twenty patients underwent PKP. Mean time of PKP was 19 months (range 11–41 months, SD
7.26) post-CLET. Median follow-up time post-PKP was 15 months (range 1–32, SD 10.2). CIC and
ICC of all corneas confirmed corneal re-epithelialization before PKP. Mean pre-PKP BCVA was
1.46 (range 0.3–2.7, SD 0.94) improving to a mean post-PKP BCVA of 0.74 (range 0–2.7, SD
0.87); mean improvement in BCVA post-PKP of 36 letters (95% CI 15.0–57.1, p5 .002). Kaplan-
Meier mean graft survival was 90.9% (95% CI 50.8–98.7) at 12 months. We recommend a two-
stage approach with CLET followed by PKP >12 months later. Patients experienced a significant
improvement in BCVA following PKP. PKP did not have a detrimental effect on CLET survival.
PKP survival post-CLET is better than that reported for high risk PKP. STEM CELLS
2018;36:925–931
SIGNIFICANCE STATEMENT
A clear cornea is essential for good vision. In severe ocular surface diseases, such as chemical
or thermal burns, there can be damage to limbal stem cells, resulting in limbal stem cell defi-
ciency (LSCD). The ocular surface in patients with unilateral total LSCD with autologous limbal
stem cell transplantation was successfully restored; however, these patients often require cor-
neal transplantation to restore their sight. This study demonstrates that these patients have an
excellent visual outcome and graft survival following corneal transplantation. A two-stage pro-
cedure was advocated in first restoring the ocular surface followed by corneal transplantation
later.
INTRODUCTION
Limbal Stem Cell Deficiency
A clear cornea is essential for good vision. In
severe ocular surface diseases, such as chemi-
cal or thermal burns, there can be damage to
limbal stem cells, resulting in limbal stem cell
deficiency (LSCD). Limbal stem cells (LSCs) are
located within crypts in a region known as the
limbus, which forms the junction between the
peripheral cornea and the sclera [1–4]. These
cells are responsible for the continuous repair
and renewal of the corneal epithelium. LSCD
results in the loss of corneal transparency due
to conjunctivalization (superficial scarring and
vascularization) of the cornea, often associated
with deep stromal opacity. LSCD can be unilat-
eral or bilateral depending on whether one
eye or both eyes are affected. Clinically, LSCD
can be classified as mild/partial, in which only
a limited part of the limbus is involved; or
severe/total, in which more than two quad-
rants of the limbus are affected combined
with central corneal involvement resulting in
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poor sight and is associated with other symptoms [5, 6].
Mild/Partial LSCD usually presents with a sectorial conjuncti-
valized area of the cornea; patients tend to experience rela-
tively mild ocular surface symptoms, with decreased vision
only if the visual axis is involved. These patients often do not
require surgical treatment. In severe cases, however, the
visual axis is often involved, leading to very low vision. This,
in combination with pain and photophobia due to recurrent
epithelial defects and chronic ocular surface inflammation,
can make the patient functionally blind [7].
Treatment of Total Limbal Stem Cell Deficiency
Total LSCD can be treated by replacing the limbal stem cell
(LSC) population. This is accomplished either by using whole-
tissue grafts or by transplanting ex vivo cultured limbal cells
(or cells from other source tissues) [8–10]. In the past 19
years, treatment of severe/total LSCD has been mainly
achieved by transplantation of ex vivo expanded LSCs cultured
from a small biopsy of the limbus from a healthy contralateral
eye (autologous, in unilateral cases) [1, 11–15], from a donor
(allogeneic, in bilateral cases) [16], or from ex vivo cultivated
oral mucosa autograft (EVOMAU) [17, 18]. The deeply scarred
cornea can then be replaced by corneal transplantation (pene-
trating or lamellar keratoplasty) often as part of a two-stage
approach [19, 20]. While ex vivo expanded stem cell or tissue
transplantation alone may improve vision in these patients, a
combination of both procedures, that is, stem cell and corneal
transplantation, is often necessary to achieve optimal visual
recovery. Corneal transplantation without prior regeneration
of the corneal epithelium by stem cell transplantation inevita-
bly fails [21] in patients with severe or total LSCD.
Most large studies on stem cell transplantation have
focused primarily on the outcomes of the stem cell transplan-
tation [22]. To the best of our knowledge, very little research
has been conducted or published to date (none in the U.K.)
on the outcomes of corneal transplantation following LSC
transplantation [19, 20], particularly with respect to the long-
term survival of corneal grafts after LSCT, or the potential
impact of corneal transplantation on the grafted stem cells.
Similarly, there are no established guidelines regarding the
timing of the two-stage transplantations and/or whether they
can be combined into a single-stage procedure [11, 12].
We aimed to investigate the outcomes of penetrating ker-
atoplasty (PKP) in our cohort of patients who have received a
CLET and to determine the overall graft survival in these
patients, who would be deemed high risk due to previous
conjunctivalization and neovascularization both superficially
and at the deeper corneal stromal level. In addition, we also
investigated the potential impact of PKP on LSC survival fol-
lowing previous CLET.
MATERIALS AND METHODS
We designed a prospective, single center, interventional
cohort study involving all patients in our Medical Research
Council (MRC) U.K.-funded phase II clinical trial for the treat-
ment of unilateral total LSCD with autologous cultivated lim-
bal epithelial stem cell transplantation (CLET, n5 23).
Consecutive patients presenting to the Eye Department at the
Royal Victoria Infirmary, Newcastle upon Tyne, U.K., with
unilateral total LSCD who met the inclusion criteria (specifi-
cally, with no other associated ocular pathology as per slit
lamp biomicroscopy, tonometry, fundoscopy, B-scan ultra-
sound and electrodiagnostic testing) for our phase II clinical
trial were recruited between June 2012 and January 2015 and
followed up for 36 months post-CLET. The study was carried
out in accordance with the principles of the Declaration of
Helsinki, with approval from the local Research Ethics Com-
mittee (11/NE/0236), MHRA Clinical Trial Authorization
(17136/0254/001-0001) and under an HTA licence (11122). All
patients gave full informed consent to participate in the clini-
cal trial and to have the procedures carried out. The results
of the CLET phase II clinical trial will be presented in due
course. In this study, we only report the clinical outcomes of
the patients who subsequently underwent PKP after CLET.
Autologous Limbal Stem Cell Transplant
All patients underwent CLET using the Newcastle method,
previously described by Kolli et al. [1]. Briefly, a clinical diag-
nosis of unilateral total LSCD was confirmed in all subjects by
corneal impression cytology (CIC) (i.e., cytokeratin profiling)
and in vivo confocal microscopy (IVCM - HRT3, Heidelberg,
Germany). A limbal biopsy was taken from the healthy fellow
eye at most commonly the 12 o’clock position, but occasion-
ally the 6 o’clock position. This was immediately transferred
to the Good Manufacturing Practice (GMP) biomanufacturing
facilities and plated onto a sheet of human amniotic mem-
brane (HAM) that had been wrapped around a glass coverslip
and trapped between a second glass coverslip. The explant
culture was incubated in limbal epithelium medium (a 3:1
solution of Dulbecco’s modified Eagle’s medium and Ham’s
F12 nutrient medium, supplemented with 10% autologous
serum, 0.4 mg/ml hydrocortisone, 5 mg/ml insulin, 1.4 ng/ml
tri-iodothyronine, 24 mg adenine, 8.4 ng/ml cholera toxin, 10
ng/ml epidermal growth factor, and 1% penicillin-streptomy-
cin) at 378C and 5% CO2. The medium was exchanged every
2–3 days until a >90% confluent monolayer of epithelial cells
was seen to have populated the HAM epithelial surface. After
the successful ex vivo expansion of LSCs was confirmed,
patients underwent a superficial keratectomy, followed by
transplantation of the HAM with the overlying ex vivo
expanded ALSCs. A second HAM, epithelium side up, was
used to act as a protective bandage over the ALSCs. Both
HAM were sutured into place with separate 10-0 nylon
sutures and a bandage contact lens (22 mm) was placed at
the end of the procedure. Postoperative drops regimen con-
sisted of preservative free prednisolone acetate 1% drops two
hourly (tapered down to QDS by three months and OD from
six months postoperatively), autologous serum eye drops 50%
two hourly (continued indefinitely) and chloramphenicol 0.5%
drops four times a day (continued until the removal of the
bandage contact lens and conjunctival sutures at 8 weeks
postoperatively, after the superficial HAM had melted). Suc-
cess of CLET was determined by clinical assessment, IVCM
and CIC performed at 6-monthly intervals post-CLET.
Penetrating Keratoplasty
Following confirmation of successful CLET at 6 and 12 months
(1/– 4 weeks) after CLET, patients with logMAR visual acuities
worse than the U.K. standard for driving (0.3 logMAR, 6/12
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Snellen BCVA) were offered PKP for visual rehabilitation, to be
performed at least 12 months post-CLET.
Conventional PKP was undertaken using donor corneas
obtained from the NHS Blood and Transplant Tissue Bank,
secured with 12 3 10-0 interrupted and 1 3 11-0 continuous
nylon sutures (Ethicon, U.K.). Median PKP size was 8.0 mm
(range 7.0–8.5 mm, SD 0.35). Interrupted sutures were selec-
tively removed from 8 weeks postoperatively depending on
refraction and corneal topography. All patients were treated
post-operatively with preservative free high dose topical ste-
roid (preservative free prednisolone acetate 1%, hourly ini-
tially), tapered down to QDS by three months and OD by six
months), autologous serum eye drops 50% (often 2 hourly)
and a short course topical antibiotic (chloramphenicol 0.5%
four times a day for 4 weeks).
In some cases with visually significant cataract, PKP was
combined with cataract extraction (with or without intraocular
lens [IOL] implantation).
Outcome Measures and Statistical Analyses
Patient demographical data were recorded, including age at the
time of PKP. CLET survival prior to and after PKP was assessed
clinically with slit lamp biomicroscopy and confirmed by IVCM
and CIC. Trephined recipient corneal buttons were also examined
histologically (particularly for the absence of goblet cells) and
with immunocytochemical staining (ICC) for corneal-specific (CK3,
CK12) and conjunctival-specific (CK13, CK19) markers.
BCVA (logMAR) was measured pre-PKP and post-PKP at
regular intervals (at least 6-monthly). Differences in pre-PKP
BCVA and post-PKP BCVA were assessed by paired two-tailed
t tests. Statistical significance was determined by p< .05. All
rejection episodes (rejection type and time to rejection) or
any other post-PKP complications were recorded. Graft failure
(defined as a loss of central graft clarity) and time to failure
were also recorded. PKP graft survival was calculated using
Kaplan-Meier survival analysis.
RESULTS
Twenty-three patients underwent CLET for unilateral total
LSCD as part of our MRC-funded phase II clinical trial. All
patients suffered ocular surface burns: 3 were thermal and 20
chemical. ALSC survival was confirmed by CIC and IVCM in all
patients prior to and after PKP. Figure 1 shows IVCM micro-
graphs of the same patient before (A) and after (B) CLET,
demonstrating re-epithelialization of the corneal surface.
Twenty of these patients fulfilled the criteria of having a
BCVA worse than U.K. driving standard, and underwent PKP
(16 males, 4 females; mean age: 42.9 years, range 22–77, SD
13.6). The other three patients, whose BCVA already met the
U.K. driving standard post-CLET, required no further interven-
tion. PKP was performed at a mean time of 19 months (range
11–41 months, SD 7.26) post-CLET. All patients were phakic
before PKP. Four patients had a combined PKP with extracap-
sular cataract extraction (ECCE) and IOL implantation in the
capsular bag. Two further patients had a subsequent cataract
extraction with IOL implantation following their PKP, while
one patient remained aphakic following combined PKP with
ECCE.
Median follow-up time post-PKP was 15.0 months (range
1–32, SD 10.2). Figure 2 shows sequential color photographs
taken of a patient who underwent a PKP procedure for visual
rehabilitation following CLET, at baseline (A), 12 months post-
CLET (B) and 17 months post-PKP (C).
Clinical slit lamp assessment of the cornea prior to PKP
demonstrated a healthy, corneal phenotype epithelium in all
cases, that is, a comfortable eye, with no delayed epithelial
staining, no epithelial defect, and minimal ocular surface
inflammation.
CIC before PKP (Table 1) showed 16 corneas expressing
CK3 or CK12 or both, with four expressing neither, but also
not expressing CK13 or CK19 (i.e., double negative staining).
In these cases, the decision to proceed with PKP was made
on the grounds of the slit lamp biomicroscopic assessment of
no evidence of LSCD, and absence of Goblet cells (GC) on CIC.
Ten corneas co-expressed limited CK13 or CK19, and a further
10 corneas did not express either. There was only one CIC
with a few Goblet cells present, but limited to a small periph-
eral sector. Figure 3 shows examples of CIC in the same
patient before and after CLET, with predominantly CK13 posi-
tive cells before CLET (A) and predominantly CK12 positive
cells after CLET (B).
Figure 1. In vivo confocal microscopy micrographs showing (A) limbal stem cell deficiency (precultivated limbal epithelial stem cell
transplantation [pre-CLET]) with loss of corneal epithelial cells (i.e., conjunctivalization) and (B) post-CLET presence of corneal phenotypic
epithelial cells (denoted by arrow).
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Histological and immunocytochemistry assessment of all
excised corneal buttons (Table 1) showed a healthy corneal
epithelial cell layer, generally 3–5 cells thick. All 20 corneal
buttons expressed either CK3 or CK12 or both. Five corneas
co-expressed limited CK13 or CK19 or both; the remaining 15
did not express either CK13 or CK19. Goblet cells were
detected in one cornea, again limited to a small peripheral
sector. Figure 4 shows histological sections of the trephined
corneal button in a patient at PKP following previous CLET,
with predominantly CK12 positive cells (B) and CK13 negative
cells (C).
The final CIC following PKP (Table 1) showed 17 corneas
expressing CK3 or CK12 or both, with three not expressing
either. Twelve corneas co-expressed CK13 or CK19 in a limited
peripheral area of the sample. There were three CIC with few
GCs, also limited to a small peripheral sector. There was no sig-
nificant difference in the rates of expression of CK3/CK12 or
CK13/CK19 and presence of GCs on CIC before and after PKP,
demonstrating a stable epithelium after CLET, despite PKP.
All patients were phakic at the time of PKP. Three patients
had cataract extraction and IOL implant at the time of PKP,
one patient had cataract removal at the time of PKP but was
left aphakic. Four further patients underwent cataract extrac-
tion and IOL implant after PKP; the remaining 12 patients
were still phakic at the last follow-up. There was no significant
difference in BCVA between the phakic and pseudophakic
groups pre-PKP (p5 .08, Mann–Whitney test) or post-PKP
(p5 .31, Mann–Whitney test).
Figure 2. Sequential color slit lamp photos of two patients receiving a penetrating keratoplasty> 12 months post-cultivated limbal epi-
thelial stem cell transplantation (post-CLET). (A) and (D) portray a color photo at baseline showing signs of total limbal stem cell defi-
ciency. Asterisk (*) denotes conjunctivalized corneal surface with neovascularization. (B) and (E) are color photos 12 months post-CLET
showing signs of a successful CLET (quiet eye, reasonably clear cornea, but with residual central deep stromal opacity). (C) and (F) show
the same eyes at 36 months post-CLET. Arrow points at the limbal explant, which is in situ.
Table 1. Summary showing number of corneas expressing CK3/CK12, CK13/CK19 and showing the presence of goblet cells on corneal
impression cytology (CIC) before and after penetrating keratoplasty (PKP), and histological and immunocytochemical analysis of excised
corneal buttons for expressions of the same
Pre-PKP CIC Corneal buttons Post-PKP CIC
CK31/CK121 CK131/CK191 Goblet cells CK31/CK121 CK131/CK191 Goblet cells CK31/CK121 CK131/CK191 Goblet cells
16 10 1 20 5 1 17 12 3
Figure 3. Color micrographs of corneal impression cytology samples with double staining for CK12 and CK13 showing (A) precultivated
limbal epithelial stem cell transplantation (pre-CLET) CK13 positive (brown) cells and (B) post-CLET CK12 positive (red) cells. Scale bars
are 100 mm.
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As shown in Figure 5A, mean pre-PKP BCVA was 1.46 log-
MAR (range 0.3–2.7, SD 0.94) improving to a mean post-PKP
BCVA of 0.74 logMAR (range 0–2.7, SD 0.87, p5 .002). This
gives a mean improvement in BCVA post-PKP of 36 letters
(95% CI 15.0–57.1, p5 .002, Fig. 5B). One patient suffered
deterioration in vision post-PKP due to blunt trauma, resulting
in wound dehiscence, traumatic expulsion of their crystalline
lens and vitreous loss, resulting in a loss of 50 letters. Other-
wise, no other patient had worse vision post-PKP. In 12
patients (60%), the BCVA post-PKP met the U.K. driving stan-
dard (logMAR BCVA 0.3 or better). The reasons for the other
eight patients not meeting the U.K. driving standard BCVA are
listed in Supporting Information Table A.
Six patients (30%) had a rejection episode (all endothelial
rejections), with one of these patients suffering two rejection
episodes. Mean time post-PKP to the first rejection episode was
9.29 months (range 2–22, SD 8.50). There were three graft fail-
ures, all related to previous rejection episode. Mean time to
failure was 14.3 months (range 11–17, SD 3.06). One patient
has been subsequently successfully re-grafted, while the other
two patients are waiting to be re-grafted. Kaplan-Meier calcu-
lated mean graft survival was 90.9% (95% CI 50.8–98.7) at 12
months and 71.6% (95% CI 35.0–89.9) at 32 months (Fig. 6).
DISCUSSION
To the best of our knowledge, most large studies on autolo-
gous LSC transplantation have, understandably, focused pri-
marily on the outcomes of the stem cell transplantation [7,
15, 23–27]. There is a lack of published studies on the long-
term outcomes of corneal allografts following limbal (or other
source) stem cell transplantation [11, 12, 20, 28–31]. There is
also very little information available regarding the potential
detrimental effect of corneal transplantation on the survival
of previous stem cell transplants. Nor is it known when the
optimal time is to perform corneal transplantation with regard
to a one-stage versus a two-stage procedure [20].
Autologous CLET successfully reversed total LSCD in all our
20 consecutive cases, as demonstrated by the repopulation of a
healthy epithelium with CK3/CK12 positive cells on histological
and immunostaining analysis of corneal buttons trephined at the
time of PKP. This confirmed the slit lamp assessment that
showed clinically normal corneal epithelium without signs of
LSCD prior to PKP. We have demonstrated a good correlation
between pre-PKP CIC and the trephined recipient cornea in
terms of the expression of CK3/CK12. However, there was a
greater proportion of CIC showing CK13/CK19 expression, both
before and after PKP, owing to likely contamination from the
surrounding conjunctiva, as the majority of the trephined recipi-
ent corneas did not express these conjunctival markers.
Basu et al. demonstrated that a two-stage procedure with
an initial CLET followed by PKP is associated with significantly
better clinical outcomes compared with a single-stage proce-
dure [20]. Patients with total LSCD typically suffer with pain
and blurred vision as their primary symptoms. Kolli et al.
showed that CLET, the first step in this pathway, is effective in
reducing pain, but results in limited visual benefit due to
deep central stromal scarring in most patients [1]. We have
shown that most patients then require a corneal allograft for
Figure 4. Color micrographs of excised corneal buttons showing (A) H&E staining of a normal stratified squamous corneal epithelium (B) CK12
positive (brown) recipient corneal button epithelial cells, and (C) CK13 negative recipient corneal button epithelial cells. Scale bars are 10 mm.
Figure 5. Graphs showing mean change in BCVA before and
after PKP. (A): Mean logMAR BCVA before PKP (pre-PKP) and after
(post-PKP). Red line denotes the mean BCVA and black error bars
are standard deviations. Blue dotted line indicates U.K. driving
standard for vision (0.3 logMAR). (B): Mean change in logMAR
BCVA after PKP; p5 .002. Red line denotes mean change in BCVA
and black error bars are 95% confidence intervals. Abbreviations:
BCVA, best-corrected visual acuity; PKP, penetrating keratoplasty.
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visual rehabilitation. As per our current study design, we per-
formed a two-stage procedure in all patients.
In this study, all 20 eyes had a BCVA worse than U.K. driving
standard (0.3 logMAR). Indeed, the mean pre-PKP BCVA was
1.46 logMAR, but this improved to a mean post-PKP BCVA of
0.74 logMAR, with 12 of the 20 patients (60%) achieving BCVA
better or equal to the U.K. driving standard at a median follow-
up of 15 months. This is comparable to Basu et al.’s reported
outcome of 15/21 (71.4%) of patients achieving a BCVA of 20/
40 or better [20]. All our patients had an improvement in BCVA,
with a statistically significant mean gain of 36 letters.
Six eyes from six patients suffered at least one endothelial
graft rejection episode (30%), with 50% leading to graft failure
despite intensive treatment, although one patient only pre-
sented for treatment 10 days after the onset of rejection
symptoms. This rate of rejection is higher than that reported
for PKP generally and reflects the fact that these are grafts in
a higher risk cohort of patients due to their past ocular
pathology and the presence of corneal stromal neovasculariza-
tion. Although at the time of PKP the eyes were clinically
without signs of inflammation, we have shown in a separate
experiment (data not published yet), that cytokine levels in
tears from these eyes still show raised inflammatory markers
to be present. Tseng and Tsubota, and later Aragona and
Rolando demonstrated that the entire ocular surface acts as a
unit, with the level of inflammation in tears reflecting the
level of inflammation in the remainder of the ocular surface
unit [32, 33]. The Australian Graft Registry reported a rejec-
tion rate of 16% in PKP performed for any indication in 2015,
although they did not break down the data for high risk PKP
[34]. Nonetheless, our rate is lower than that reported for
PKP in high risk cases [35, 36]. Our failure rate following
rejection is comparable to Basu et al., who reported a 57.7%
failure rate after 1 or more episodes of endothelial rejection,
although they combined the rejection and failure data for a
single-stage and two-stage procedures [20].
We report a 90.9% corneal graft survival at 12 months
post-PKP and 71.6% at 32 months, which is lower than that
reported in the literature [34, 37]. However, it is favorable
compared with Basu et al. who reported an 80% graft survival
at 1 year in patients with previous CLET, and the Australian
Graft Registry who reported an 87% graft survival at 1 year in
patients with inflammation at the time of the graft, which
could be deemed high risk grafts [20, 34]. Basu et al. described
a two-stage approach as being advantageous in terms of cor-
neal graft survival, and they defined this as having a PKP at
least 6 weeks following CLET [20]. Following our phase I clinical
trial [1], our protocol has been to delay PKP until at least 12
months following CLET to ensure an eye that is completely
quiet in terms of ocular surface inflammation, and this could
explain our favorable graft survival rate at 1 year.
There was no evidence that PKP had a detrimental effect
on LSC survival following previous CLET in the same eye, dem-
onstrated by slit lamp biomicroscopy showing an absence of
signs of recurrent LSCD. This was confirmed by the lack of a
significant change in the expression of CK3/CK12, CK13/CK19,
or the presence of GCs on CIC before and after PKP. To the
best of our knowledge, other studies have not yet reported
on the impact of corneal transplantation following previous
LSC transplantation on LSC survival.
CONCLUSION
In summary, our results support Basu et al.’s study favoring a
two-stage approach to visual rehabilitation in patients with
total LSCD who underwent CLET in the same eye. However, in
contrast to Basu et al., we recommend a delay of at least 12
months following CLET before proceeding with PKP, aiming to
have a very quiet eye before corneal transplantation. This is
supported by our favorable corneal graft survival outcomes at
1 year. Patients with previous CLET remain a slightly high-risk
group for corneal allografts, reflected by their survival rates
being slightly worse than low-risk PKP, but better than pub-
lished data for high-risk PKP. To the best of our knowledge, we
are the first to report on the outcomes of CLET following PKP.
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